Literature DB >> 33910857

Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study.

Tomoki Tamura1, Keita Kawakado2, G O Makimoto2, Masamoto Nakanishi2, Shoichi Kuyama2.   

Abstract

BACKGROUND: The guidelines on pharmacotherapy for cancer-related pain advocate active measures against the adverse effects of opioids to increase adherence to medication. However, preventative therapy for the management of nausea and vomiting has not been specified. This study aimed to verify the effects of prophylactic anti-emetics in preventing opioid-induced nausea and vomiting. PATIENTS AND METHODS: We conducted a retrospective analysis of cases at our hospital in which oral opioids or patches were initiated for the management of pain due to malignant tumours from January 2017 to September 2019.
RESULTS: Strong opioids were initiated for 349 patients; of these, data for 298 patients were analysed. A total of 193 patients were on anti-emetic prophylaxis. We found that the group that did not receive anti-emetic prophylaxis was significantly more likely to be prescribed an additional anti-emetic.
CONCLUSION: Prophylactic administration of anti-emetics at the time of initiating opioid analgesics may reduce gastrointestinal toxicity. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Anti-emetics; emesis; nausea; opioids

Mesh:

Substances:

Year:  2021        PMID: 33910857      PMCID: PMC8193312          DOI: 10.21873/invivo.12432

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  15 in total

Review 1.  Clinical guideline for pharmacological management of cancer pain: the Japanese Society of Palliative Medicine recommendations.

Authors:  Takashi Yamaguchi; Yasuo Shima; Tatsuya Morita; Miki Hosoya; Motohiro Matoba
Journal:  Jpn J Clin Oncol       Date:  2013-07-23       Impact factor: 3.019

2.  Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.

Authors:  Hiroaki Tsukuura; Yuichi Ando; Bishal Gyawali; Masami Matsumoto; Mihoko Sugishita; Kazunori Honda; Hiroshi Urakawa; Osamu Maeda; Yoshinori Hasegawa
Journal:  J Palliat Med       Date:  2015-08-20       Impact factor: 2.947

3.  Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting: a survey about Italian physicians' practice.

Authors:  Raffaele Giusti; Marco Mazzotta; Marco Filetti; Gennaro Daniele; Hiroaki Tsukuura; Corrado Ficorella; Giampiero Porzio; Paolo Marchetti; Lucilla Verna
Journal:  Support Care Cancer       Date:  2019-01-26       Impact factor: 3.603

4.  The Management of Opioid-Induced Nausea and Vomiting in Patients with Cancer: A Systematic Review.

Authors:  Tonje A Sande; Barry J A Laird; Marie T Fallon
Journal:  J Palliat Med       Date:  2018-09-21       Impact factor: 2.947

Review 5.  2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer.

Authors:  Declan Walsh; Mellar Davis; Carla Ripamonti; Eduardo Bruera; Andrew Davies; Alex Molassiotis
Journal:  Support Care Cancer       Date:  2016-08-17       Impact factor: 3.603

Review 6.  Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations.

Authors:  Eivor A Laugsand; Stein Kaasa; Pål Klepstad
Journal:  Palliat Med       Date:  2011-07       Impact factor: 4.762

7.  The Burden of Opioid Adverse Events and the Influence on Cancer Patients' Symptomatology.

Authors:  Oscar Corli; Claudia Santucci; Nicole Corsi; Silvia Radrezza; Francesca Galli; Cristina Bosetti
Journal:  J Pain Symptom Manage       Date:  2019-02-16       Impact factor: 3.612

8.  Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.

Authors:  Hiroaki Tsukuura; Masayuki Miyazaki; Tatsuya Morita; Mihoko Sugishita; Hiroshi Kato; Yuka Murasaki; Bishal Gyawali; Yoko Kubo; Masahiko Ando; Masashi Kondo; Kiyofumi Yamada; Yoshinori Hasegawa; Yuichi Ando
Journal:  Oncologist       Date:  2017-10-16

9.  Pharmaceutical interventions facilitate premedication and prevent opioid-induced constipation and emesis in cancer patients.

Authors:  Masashi Ishihara; Hirotoshi Iihara; Shinji Okayasu; Koji Yasuda; Katsuhiko Matsuura; Masumi Suzui; Yoshinori Itoh
Journal:  Support Care Cancer       Date:  2009-11-18       Impact factor: 3.603

10.  Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary?

Authors:  Yuko Kanbayashi; Toyoshi Hosokawa
Journal:  J Palliat Med       Date:  2014-04-04       Impact factor: 2.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.